On June 29, 2026, Ascentage Pharma Group International announced the further grant of awards under its 2021 and 2022 Restricted Share Unit (RSU) schemes, as well as the further grant of options under its Post IPO Share Option Scheme. The company operates in the biotechnology industry and develops innovative small molecule drugs for oncology and hematology.
